SpecialtiesQuestion

What prognostic models have been developed to predict HCC risk in HCV patients post-SVR?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

What clinical features would raise your suspicion for IgG-4 related disease?

How do you adjust transplant-benefit–based decision-making for HCC patients with prior immune checkpoint inhibitor exposure, given the potential for increased peri-transplant rejection or graft loss?

As first-line systemic therapy outcomes improve for advanced HCC (e.g., immune checkpoint inhibitor–based combinations), how would you adjust the threshold at which you would recommend liver transplantation within a transplant-benefit framework?

When assessing whether an HCC multidisciplinary clinic is improving outcomes beyond stage migration, which patient-level, clinically actionable metrics do you track (e.g., time-to-treatment, guideline-concordant therapy, successful bridging/downstaging, treatment sequencing changes)?

For early HCC that is technically within transplant criteria, what patient- or tumor-related features (e.g., AFP behavior, frailty, rising MELD, multifocality) lead you to stop pursuing liver transplantation as the preferred strategy and instead recommend resection/ablation with surveillance?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.